Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This chapter reviews the role of androgen receptors in mediating the actions of androgens in specific tissues and provides no new experimental findings.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.

This review examines hair and skin disorders in post-menopausal women and notes a lack of evidence supporting specific treatments for this population.

This review discusses the role of the androgen receptor in breast cancer diagnosis and treatment, and notes a lack of new research results on its therapeutic potential.

This review discusses various aspects of unwanted facial hair, including its psychological impact and current treatment options, and reports no new clinical results from the satellite symposium at the EHRS Meeting.

This chapter reviews selective androgen receptor modulators, discussing their therapeutic potential beyond current androgen applications, and reports no new clinical findings.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

This article discusses diagnostic and treatment options for excessive hair growth in women, noting a need for holistic approaches to address associated psychological issues, but it does not present new clinical findings.

This review discusses potential treatments for androgen excess in polycystic ovary syndrome and reports no new findings, emphasizing the importance of individualized antiandrogenic management to minimize side effects.

This review discusses the role of dermatologists in diagnosing and treating PCOS-related dermatological manifestations, emphasizing the importance of early intervention to enhance patients' quality of life, but reports no new clinical findings.

This review discusses the potential link between androgenic alopecia, androgens, and the severity of COVID-19, highlighting possible therapeutic targets but reports no new clinical results.

This article presents guidelines developed by a multidisciplinary expert panel for the care of adolescent transgender and non-binary individuals with gender dysphoria, emphasizing individualized, affirmative care to enhance well-being and quality of life.

This review found that patients taking antiandrogens, 5 alpha-reductase inhibitors, and spironolactone have an increased risk of developing gynecomastia, potentially due to hormonal changes.

This review examines changes in hair physiology and treatment options for transgender patients on hormonal therapy but reports no new clinical findings, offering treatment recommendations based on the authors' experiences.

This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.

This study found that treating androgenetic alopecia through a virtual healthcare platform significantly improved hair-loss-related quality of life over six months, with adherence to the program being a key factor in achieving better outcomes among the participants in Brazil.

This study reviews current pharmacological treatments for alopecia, highlighting minoxidil, 5α-reductase inhibitors, JAK inhibitors, and other agents, and notes ongoing research aimed at improving their effectiveness and safety profiles.

In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

In this study, researchers explored the use of a 2-deoxy-D-ribose sodium alginate hydrogel on mice with androgenic alopecia and found it resulted in similar hair regrowth to minoxidil, highlighting increased hair follicle density and angiogenesis.

In this study, low-dose oral minoxidil was found to improve hair density in 80% of pediatric patients with androgenetic alopecia or telogen effluvium, with mild side effects primarily reported.

In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.

Most young patients found oral minoxidil helpful for hair loss and were willing to continue using it.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

This review highlights the challenges and management strategies associated with persistent chemotherapy-induced alopecia, detailing the psychosocial impacts, follicular pathobiology, and available treatments such as scalp cooling and minoxidil, ultimately proposing a clinical algorithm to transform it into a preventable and manageable condition.

This study indicates that finasteride use may lower bladder cancer incidence, while androgen suppression therapy improves recurrence-free survival but not other survival outcomes in bladder cancer patients.

This study found that androgen suppression therapy did not significantly reduce bladder cancer incidence overall but suggested finasteride use might lower the risk; recurrence-free survival was improved among AST users.